Drugs in MeSH Category HIV Integrase Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Sub Merck	ISENTRESS	raltegravir potassium	TABLET;ORAL	022145-001	Oct 12, 2007		RX	Yes	Yes					Y
Lupin Ltd	RALTEGRAVIR POTASSIUM	raltegravir potassium	TABLET;ORAL	217990-001	May 6, 2025	AB	RX	No	No
Msd Sub Merck	ISENTRESS HD	raltegravir potassium	TABLET;ORAL	022145-002	May 26, 2017	AB	RX	Yes	Yes					Y

Market Dynamics and Patent Landscape for NLM MeSH Class: HIV Integrase Inhibitors

Last updated: April 26, 2026

What is the current market structure for HIV integrase inhibitors?

HIV integrase inhibitors (INIs) sit in the center of antiretroviral therapy regimens because they enable potent viral suppression with favorable tolerability profiles. In practice, INIs are used mainly in fixed-dose combination (FDC) products and as components of single-tablet regimens (STRs), which concentrates demand around branded, payer-supported offerings rather than standalone INI monotherapy.

Demand drivers

• Regimen role: INIs are routinely selected as backbone therapy in first-line and treatment-switch strategies because of rapid viral load reduction and durable efficacy across diverse patient populations.
• Formulation channel: Most patient access is through FDC/STR products, increasing the commercial value of patent-protected combination formulations and line extensions.
• Health system procurement: Public tenders in high-burden geographies favor cost-competitive generics only after loss of exclusivity; before then, branded supply dominates.
• Resistance management: Clinical need for INIs that maintain activity in the presence of integrase resistance mutations supports continued differentiation among molecules.

Commercial reality by molecule class

The integrase inhibitor market is dominated by:

• INSTIs with high barrier to resistance and widespread guideline inclusion, led by dolutegravir and bictegravir in FDC/STRs.
• Rarer adoption or narrower positioning for products with more constrained use patterns due to drug-drug interaction management or population-specific restrictions (varies by jurisdiction and label).

Which INI drugs define today’s IP and commercial landscape?

The MeSH category “HIV Integrase Inhibitors” aligns with the INSTI drug class used in antiretroviral therapy. The patent landscape is molecule- and formulation-driven, with exclusivity also shaped by:

• Second medical uses (population-specific dosing, pregnancy or renal impairment use)
• Pharmaceutical formulations (crystalline form, particle size, co-crystals, FDC stability)
• Method-of-treatment claims (resistance profiles, treatment-naïve vs experienced strategies)
• Manufacturing/process claims (often more relevant for blocking generic entry where product claims are exhausted)

How does the patent landscape break down by drug molecule?

Below is the practical IP map for the HIV integrase inhibitor ecosystem: who owns the core molecule IP, where downstream patents cluster (formulations and uses), and the typical expiration pressure points that shape generic timelines.

Dolutegravir (DTG)

Market role

• Backbone INSTI in high-coverage FDCs and STRs.

Patent landscape dynamics

• Core molecule IP and related salts/polymorph coverage anchored early.
• The major “late-stage” protection tends to sit in:
  • FDC combinations (dolutegravir/lamivudine or dolutegravir with other nucleosides)
  • Crystalline form and solid-state improvements
  • Pediatric dosing and formulation (syrups, dispersible tablets, weight-band tablets)
  • New dosing regimens (including pharmacokinetic-driven adjustments and combination-specific dose rules)

Commercial implication

• Generic entry tends to occur later for specific FDCs and pediatric formulations even when a standalone molecule has earlier generic availability.

Bictegravir (BIC)

Market role

• Strong uptake through STR positioning.

Patent landscape dynamics

• Core molecule protection plus STR-specific coverage creates prolonged exclusivity windows by product form.
• Patent thickets often include:
  • Combination formulation stability (solid state and dissolution)
  • Dose regimens and clinical claims tied to specific STR compositions
  • Solid form optimization

Commercial implication

• Even where generic INSTI molecules enter, STR-level patent barriers can delay meaningful substitution.

Raltegravir (RAL)

Market role

• Earlier INSTI; more constrained than DTG/BIC due to competitive and guideline shifts.

Patent landscape dynamics

• Many core patents have lapsed in major markets; surviving protections (if any) are typically formulation or method-of-use.

Commercial implication

• Lower brand premium than DTG/BIC-era products; substitution tends to be faster once generic access is available.

Elvitegravir (EVG) and boosted formulations

Market role

• Often paired with pharmacokinetic boosters (cobicistat) in combination products.

Patent landscape dynamics

• IP pressure frequently relates to:
  • Boosting regimens
  • FDC combinations
  • Solid-state and stability improvements

Commercial implication

• Competition depends heavily on the specific boosted FDC and whether its formulation is still protected.

Cabotegravir is not a classic daily INSTI

Market role

• Long-acting injectable INSTI positioning with distinct IP and market access dynamics.

Patent landscape dynamics

• Large portion of exclusivity tends to attach to:
  • Long-acting injectable compositions
  • Dosing schedules and initiation methods
  • Device and formulation constraints tied to delivery

Commercial implication

• Longer runway for branded supply if sustained around injectable-specific patents.

Which patents typically control exclusivity and generic entry?

For HIV INIs, the “blocking layer” is rarely only the primary active ingredient composition. It is the downstream bundle of:

1. Salt forms and co-crystals
2. Solid-state forms (polymorphs, hydrates, amorphous grades)
3. Manufacturing/process steps that produce a distinct solid form or improve dissolution
4. Combination products (FDC and STR claims)
5. Method-of-use claims tied to:
   • baseline resistance mutation status
   • treatment-naïve vs experienced populations
   • specific dosing in special populations
   • drug-drug interaction guidance for boosted or co-administered regimens

This is the standard pattern in mature HIV small-molecule IP: core substance claims often fall earlier than formulation and use claims for specific commercial SKUs.

How do regulatory exclusivities interact with patent expiry?

In the US and EU, market exclusivity timing is not purely patent-driven. It often combines:

• Patent term (composition, formulation, method)
• Regulatory data exclusivity and related protections for first approvals of specific products
• Pediatric exclusivity where applicable
• Orphan incentives only when relevant to specific indications

For business planning, the operational takeaway is that generic launch calendars must be built around:

• product-specific exclusivity, not only molecule-specific expiry
• FDC/STR composition-specific patent stacks

What patent filing patterns matter for new entrants and biosimilar-style strategies?

The INI space is a “small-molecule, generic entry constrained by product claims” market. New entrants generally face:

• Line extension filings that target:
  • improved dissolution profiles
  • easier manufacturing
  • better pediatric palatability and dosing flexibility
  • reduced food effect
• “Evergreening” via formulation rather than new clinical indications (though method-of-use can also be protected)

From an investment perspective:

• If a company wants to launch at risk, it must clear not only API patents but also the solid-state and FDC-specific layers.
• If it wants a launch without litigation, it must wait for the last blocking product claim that corresponds to the intended commercial SKU.

Which markets show the most predictable substitution behavior?

Substitution is fastest where:

• branded patents are weak or already lapsed
• the intended launch form is not protected as an FDC/STR
• health authorities accept bioequivalent substitution without additional clinical bridging complexity

Substitution is slower where:

• FDC or STR patents remain active
• pediatric formulations are separately protected
• long-acting injectable platforms carry distinct formulation and dosing protection

Practical market ordering (typical pattern)

• Standalone tablets and simple API entries generally substitute earlier.
• STRs and FDCs substitute later due to additional combination formulation IP.
• Long-acting injectables substitute last due to layered formulation and method-of-use claims.

What does this mean for pipeline and R&D prioritization?

R&D in INIs is constrained by a crowded core efficacy landscape; the defensible pathways usually include:

• New formulations for ease of use and adherence
• New dosing regimens that improve pharmacokinetics in real-world co-medication settings
• New delivery formats (where feasible)
• New combinations that preserve clinical benefit while avoiding rapid generic substitution

For patent strategy:

• The “value unit” is the commercial product SKU. Patents should cover the SKU, not only the active ingredient.

Key takeaways

• HIV integrase inhibitors are dominated by INSTI backbone use in STR and FDC products, shifting IP value toward combination formulations and solid-state variants.
• Patent landscape risk for generic entry is highest at the FDC/STR and formulation layer, not only the core molecule.
• Market substitution timing is predictable: API and simple formulations typically face earlier generic entry than STR/FDC and long-acting injectable products.
• Future differentiation and defensibility for new entrants is usually achieved through formulation, delivery, and regimen claims aligned to the target SKU.

---

FAQs

1) Why do FDC and STR patents matter more than the base active ingredient in INIs?
Because most patient demand is captured through branded fixed combinations, and downstream claims on the specific combination formulation, solid-state form, and dosing methods can remain enforceable even when the base molecule patents have lapsed.

2) What patent types most often block generic launches for INI products?
Solid-state and formulation patents (polymorphs, hydrates, particle size, co-crystals), process/manufacturing patents tied to producing those forms, and FDC/STR composition-specific claims.

3) How does resistance management affect patent and clinical positioning in INIs?
Products that maintain activity against resistance-associated mutations support method-of-use and regimen claims that can extend exclusivity tied to clinical use patterns.

4) What is the typical substitution sequence across INI formats?
Standalone formulations generally substitute earlier than STR/FDCs, and long-acting injectables typically substitute last due to layered formulation and regimen IP.

5) What is the main commercial implication for new entrants?
Launch planning must be SKU-specific. The target product’s patent stack, especially for formulations and combinations, drives the feasible entry window and litigation risk more than molecule-level expiry.

---

References

[1] National Library of Medicine. MeSH: “HIV Integrase Inhibitors.” https://www.ncbi.nlm.nih.gov/mesh/